Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies to address the major challenges with current cancer therapy. Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies. KVA12123, Kineta's lead asset, is potentially a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment (TME). Kineta has dosed the first patient in a Phase 1 /Phase 2 clinical study evaluating KVA12123 as a single agent and in combination with (pembrolizumab) in patients with advanced solid tumors. Initial safety data is anticipated in Q3 2023 with initial efficacy data anticipated in Q4 2023. Kineta is also advancing an anti-CD27 agonist mAb for advanced solid tumors and anticipates filing an IND in 2H 2024.